LI∆E6E7

LI∆E6E7 is an **attenuated recombinant Listeria innocua bacterial vaccine vector** engineered to express a fusion antigen of the E6 and E7 oncogenes of human papillomavirus type 16 (HPV16). The strain is genetically modified with deletions in actA and plcB, leading to significant attenuation and reduced virulence in vivo. In preclinical models, LI∆E6E7 is investigated as a **therapeutic immunotherapy candidate for HPV-associated cancer**, especially cervical cancer. Immunotherapy with LI∆E6E7, often in combination with an analogous Listeria monocytogenes vector (LM∆E6E7), has shown anti-tumor effects, enhancing CD8+ T cell and NK cell activity, and reducing immunosuppressive myeloid-derived suppressor cells (MDSCs) by modulation of JAK-STAT signaling. The recombinant bacteria display a preference for liver localization after intravenous administration and are cleared from organs (liver, spleen) within two weeks, supporting a favorable safety profile in animal models[1][2].

Other names

LIΔ-E6E7LI∆-E6E7